Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting study;¿impacta el criterio para indicar la biopsia prostática sobre su exactitud? Estudio prospectivo llevado a cabo sobre una población de pacientes ambulantes

Actas Urologicas Espanolas

Volumn 35, Issue 1, 2011, Pages 10-14

  Reis, L O ^a,b   Zani, E L ^a   Alonso, J C ^b   Simoes F A ^b   Rejowski, R F ^b   Ferreira, U ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Hospital Municipal de Paulinia   (Brazil)

Author keywords

Accuracy; Diagnosis; Digital rectal examination; Prostate biopsy; Prostate cancer; PSA derivatives

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; AMBULATORY CARE; ARTICLE; BLOOD; HUMAN; MALE; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; REPRODUCIBILITY; STANDARD;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 79151485525     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2010.06.011     Document Type: Article

References (25)

1. W.J. Catalona, J.P. Richie, F.R. Ahmann, M.A. Hudson, P.T. Scardino, and R.C. Flanigan Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men J Urol. 151 1994 1283 1290
2. W.J. Catalona, D.S. Smith, T.L. Ratliff, and J.W. Basler Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening JAMA. 270 1993 948 954
3. J.P. Richie, W.J. Catalona, F.R. Ahmann, M.A. Hudson, P.T. Scardino, and R.C. Flanigan Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination Urology. 42 1993 365 374
4. H.B. Carter A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older Urology. 55 2000 796 799
5. W.J. Catalona, C.G. Ramos, G.F. Carvalhal, and Y. Yan Lowering PSA cutoffs to enhance detection of curable prostate cancer Urology. 55 2000 791 795
6. P.H. Gann, C.H. Hennekens, and M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA. 273 1995 289 294
7. A. Heidenreich, G. Aus, M. Bolla, S. Joniau, V.B. Matveev, and H.P. Schmid EAU guidelines on prostate cancer Actas Urol Esp. 33 2009 113 126
8. A.W. Partin, M.K. Brawer, E.N. Subong, C.A. Kelley, J.L. Cox, and D.J. Bruzek Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer Prostate Cancer Prostatic Dis. 1 1998 197 203
9. W.J. Catalona, A.W. Partin, K.M. Slawin, M.K. Brawer, R.C. Flanigan, and A. Patel Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA. 279 1998 1542 1547
10. Y. Kobori, Y. Kitagawa, A. Mizokami, K. Komatsu, and M. Namiki Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1-10.0 ng/mL as a criterion Int J Clin Oncol. 13 2008 229 232
11. K.A. Roehl, J.A. Antenor, and W.J. Catalona Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/mL range J Urol. 168 2002 922 925
12. M. Lujan, A. Paez, L. Llanes, E. Miravalles, and A. Berenguer Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? Prostate Cancer Prostatic Dis. 4 2001 146 149
13. W.J. Catalona, J.P. Richie, J.B. deKernion, F.R. Ahmann, T.L. Ratliff, and B.L. Dalkin Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves J Urol. 152 6 Pt 1 1994 2031 2036
14. C. Stephan, G. Stroebel, M. Heinau, A. Lenz, A. Roemer, and M. Lein The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL Cancer. 104 2005 993 1003
15. W.J. Catalona, P.C. Southwick, K.M. Slawin, A.W. Partin, M.K. Brawer, and R.C. Flanigan Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging Urology. 56 2000 255 260
16. H.B. Carter, L. Ferrucci, A. Kettermann, P. Landis, E.J. Wright, and J.I. Epstein Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst. 98 2006 1521 1527
17. S. Loeb, K.A. Roehl, R.B. Nadler, X. Yu, and W.J. Catalona Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/mL J Urol. 178 2007 2348 2352
18. R.M. Stopiglia, U. Ferreira, M.M. Silva Jr., W.E. Matheus, F. Denardi, and L.O. Reis Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial J Urol. 183 2010 940 944
19. A.J. Vickers, C. Savage, M.F. O'Brien, and H. Lilja Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer J Clin Oncol. 27 2009 398 403
20. L. Sun, J.W. Moul, J.M. Hotaling, E. Rampersaud, P. Dahm, and C. Robertson Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 99 2007 753 757
21. S. Loeb, and W.J. Catalona What to do with an abnormal PSA test Oncologist. 13 2008 299 305
22. F.H. Schroder, and M.J. Roobol Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer Curr Opin Urol. 19 2009 227 231
23. T.A. Stamey, M. Caldwell, J.E. McNeal, R. Nolley, M. Hemenez, and J. Downs The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 172 2004 1297 1301
24. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd, S.S. Buys, D. Chia, and T.R. Church Mortality results from a randomized prostate-cancer screening trial N Engl J Med. 360 2009 1310 1319 Erratum in: N Engl J Med. 2009;360:1797
25. F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, and V. Nelen Screening and prostate-cancer mortality in a randomized European study N Engl J Med. 360 2009 1320 1328